Navigation Links
Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
Date:4/7/2009

CALGARY, April 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced positive results in its U.K. Phase II clinical trial to evaluate the objective tumour response rate of REOLYSIN(R) in combination with low-dose radiation in patients with advanced cancers.

A total of 16 heavily pretreated patients with advanced cancer (melanoma (5), colorectal (4), gastric (1), pancreas (1), ovarian (1), lung (1), cholangiocarcinoma (1), sinus (1), and thyroid (1)) were enrolled in the trial. Most patients had received prior chemotherapy (13 patients) or radiation (5 patients). Of 14 patients evaluable for response, 13 patients had stable disease (SD) or better in the treated target lesions. Of these, partial responses (PR) were observed in four patients (lung, melanoma (2) and gastric) and minor responses were observed in two patients (thyroid, ovarian), for a total disease control rate (stable disease + partial response + complete response) of 93% in the treated lesions. The combination was well tolerated, with only mild (Grade 1 or 2) toxicities noted.

"This is a very high disease control rate in patients who have undergone prior therapies," said Dr. Brad Thompson, President and CEO of Oncolytics. "This combination resulted in marked responses or stabilization in the treated target lesions for most of the patients. These results are expected to allow us to pursue REOLYSIN in combination with radical radiotherapy in future clinical trials."

The trial (REO 008) was an open-label, single-arm, multi-centre Phase II study of REOLYSIN delivered via intratumoural injection to patients during treatment with low-dose fractionated radiotherapy. 20 Gy of radiation was given in five consecutive daily 4 Gy fractions combined with two intratumoural injections of REOLYSIN (1x10(10) TCID(50)) on days two and four. The p
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The ... -12, at the Ernest N. Morial Convention Center ... (count as of February 19, 2015) displaying products ... industrial, academic, and government labs. The Exposition will ... but not limited to, analytical chemistry; drug discovery; ...
(Date:2/26/2015)... Frederick, MD (PRWEB) February 26, 2015 ... solutions provider, released FreezerPro® version 6.2 – the latest ... The FreezerPro® reputation is that of a quick and ... related work. With the latest version, RURO engineering has ... on import to move large amounts of sample records. ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2RURO Releases FreezerPro® version 6.2 2Regis Extends cGMP Services to Oncology Market 2
... Jan. 8 Substantial progress and,momentum behind its research-and-development ... deliver several new blockbuster products to farmers,by 2012, company ... part of a series of presentations on the company,s ... to see such innovation in the pipeline right now," ...
... would, strengthen Elekta,s offering and accelerate the company,s expansion ... ... Elekta AB (publ) (STO: EKTAb),a world leader in clinical solutions ... exclusive negotiations based on,a Letter of Intent to acquire CMS ...
... and patients of,community-based medical practices in ... partnership between Physicians Practice and Loma ... help local physicians manage their,practices more ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/NETU093LOGO ), Under ...
Cached Biology Technology:Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 2Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 3Elekta Negotiates To Acquire CMS 2Elekta Negotiates To Acquire CMS 3Elekta Negotiates To Acquire CMS 4Elekta Negotiates To Acquire CMS 5Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California 2
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... CHAMPAIGN, Ill. We all know one, or think we ... his or her actual merits. Popular culture labels these folks ... suggests that some forms of narcissism are at least ... difficult transition to adulthood. The study appears ...
... relatively simple combination of naturally occurring sugars and amino acids ... according to a paper published in Nature Chemistry ... The study, " A Route to Enantiopure RNA Precursors ... to RNA could have formed on Earth before any life ...
... --- Farmers and policymakers should wait before converting Conservation Reserve ... Michigan State University study. The study, which appears ... National Academy of Sciences , focuses on CRP land, a ... than crops, and its role in the production of biofuels. ...
Cached Biology News:Narcissism may benefit the young, researchers report; but older adults? Not so much 2To avoid carbon debt, CRP beats fields of corn, soybeans 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Yeast Oligo Microarray Kit (V2), 2 ... simultaneously characterize expression of many thousands ... activity during important biological processes. Each ... 6,256 known ORFs from the S288C ...
... an intuitive, easy-to-use operating environment ... data handling, and integration with ... include data acquisition, re-analysis, custom ... both standalone and network environments. ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
Biology Products: